Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Chipman, M. Agbandje-McKenna, S. Kajigaya, K. Brown, N. Young, T. Baker, M. Rossmann (1996)
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor.Proceedings of the National Academy of Sciences of the United States of America, 93 15
H. Towbin, T. Staehelin, J. Gordon (1979)
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences of the United States of America, 76 9
A. Anand, E. Gray, T. Brown, J. Clewley, B. Cohen (1987)
Human parvovirus infection in pregnancy and hydrops fetalis.The New England journal of medicine, 316 4
C. Brown, J. Lent, J. Vlak, Willy Spaan (1991)
Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteinsJournal of Virology, 65
Woolf Woolf, Campion Campion, Chishick Chishick, Wise Wise, Cohen Cohen, Klouda Klouda, Caul Caul, Dieppe Dieppe (1989)
Clinical manifestations of human parvovirus B19 in adultsArch Intl Med, 149
R. Franssila, M. Söderlund, C. Brown, W. Spaan, I. Seppälä, K. Hedman (1996)
IgG subclass response to human parvovirus B19 infection.Clinical and diagnostic virology, 6 1
K. Ozawa, J. Ayub, Y. Hao, G. Kurtzman, T. Shimada, N. Young (1987)
Novel transcription map for the B19 (human) pathogenic parvovirusJournal of Virology, 61
T. Török (1997)
Unusual Clinical Manifestations Reported in Patients with Parvovirus B19 Infection, 20
C. Brown, M. Salimans, M. Noteborn, H. Weiland (1990)
Antigenic parvovims B19 coat proteins VP1 and VP2 produced in large quantities in a baculovirus expression systemVirus Research, 15
M. Söderlund, C. Brown, Willy Spaan, L. Hedman, Klaus Hedman (1995)
Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.The Journal of infectious diseases, 172 6
M. Anderson, S. Jones, S. Fisher-Hoch, E. Lewis, S. Hall, C. Bartlett, B. Cohen, P. Mortimer, M. Pereira (1983)
HUMAN PARVOVIRUS, THE CAUSE OF ERYTHEMA INFECTIOSUM (FIFTH DISEASE)?The Lancet, 321
G. Kurtzman, K. Ozawa, B. Cohen, G. Hanson, R. Oseas, N. Young (1987)
Chronic bone marrow failure due to persistent B19 parvovirus infection.The New England journal of medicine, 317 5
U. Laemmli (1970)
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 227
K. Brown (1997)
Human Parvovirus B19 Epidemiology and Clinical Manifestations, 20
A. Woolf, G. Campion, Alice Chishick, S. Wise, B. Cohen, P. Klouda, Owen Caul, P. Dieppe (1989)
Clinical manifestations of human parvovirus B19 in adults.Archives of internal medicine, 149 5
G. Serjeant, B. Serjeant, P. Thomas, M. Anderson, G. Patou, J. Pattison (1993)
Human parvovirus infection in homozygous sickle cell diseaseThe Lancet, 341
J. Lefrère, A. Couroucé, Y. Bertrand, R. Girot, J. Soulier (1986)
Human parvovirus and aplastic crisis in chronic hemolytic anemias: A study of 24 observationsAmerican Journal of Hematology, 23
F. Morinet, L. d'Auriol, J. Tratschin, F. Galibert (1989)
Expression of the human parvovirus B19 protein fused to protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera.The Journal of general virology, 70 ( Pt 11)
Recombinant versions of parvovirus B19 capsid proteins VP1 and VP2 are used for immunodiagnostic assays for detection of antiviral antibodies. The immune response to B19 is characterized by a gradual loss of antibodies directed against linear epitopes of VP2. A similar occurrence for antibodies raised against VP1 protein would represent a limitation to serological assays incorporating denatured versions of either viral antigen. Four detection systems for B19 Ig detection have been developed, including an IgG enzyme immunoassay (EIA) based on undenatured VP2, an immunofluorescence assay (IFA) based on undenatured VP1, a Western blot assay incorporating denatured VP1 and VP2, and an alternative blot system using denatured VP1 but undenatured VP2. Specimens (n = 108) were tested by all four systems and identical results were obtained by EIA, IFA, and alternative blot systems, whereby 75/108 (69%) were B19 IgG‐positive. Twelve B19 IgG‐positive specimens, representing 16% (12/75) of the confirmed positives, did not react to either viral antigens when tested by Western blot. It is concluded that these sera do not react with linear epitopes of VP1 and VP2 antigens. Eighty‐five different specimens, which had previously been shown to be both B19 IgM‐ and IgG‐positive by EIA and IFA, were positive by B19 IgM and IgG Western blot. In the IgG Western blot assay, 69 reacted with both VP1 and VP2 and 16 with VP1 only. It is concluded that there is a requirement for at least one undenatured antigen for the immunological detection of B19 IgG. J. Med. Virol. 57:179–185, 1999. © 1999 Wiley‐Liss, Inc.
Journal of Medical Virology – Wiley
Published: Feb 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.